Overcoming therapy resistance in pancreatic cancer: New insights and future directions
-
Published:2024-11
Issue:
Volume:229
Page:116492
-
ISSN:0006-2952
-
Container-title:Biochemical Pharmacology
-
language:en
-
Short-container-title:Biochemical Pharmacology
Author:
Espona-Fiedler MargaritaORCID,
Patthey Cedric,
Lindblad Stina,
Sarró Irina,
Öhlund Daniel
Reference204 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin,2021
3. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice;Collins;J. Clinical Invest.,2012
4. Daoud, A. Z., Mulholland, E. J., Cole, G. & McCarthy, H. O. MicroRNAs in Pancreatic Cancer: Biomarkers, prognostic, and therapeutic modulators. BMC Cancer vol. 19 Preprint at https://doi.org/10.1186/s12885-019-6284-y (2019).
5. Genomic analyses identify molecular subtypes of pancreatic cancer;Bailey;Nature,2016